ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...
Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD; U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment; Notic ...
Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
Over the past few decades, engineers have developed various devices that can create holograms, three-dimensional (3D) or ...
Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPDU.S. patent to expire in March 2043, including 1,095 days of Patent Term AdjustmentNotice of allowance also recei ...
Top line data readout expected in late Q3/early Q4; INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase ...
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...
Researchers at the Oak Ridge National Laboratory National Transportation Research Center have designed a ...